# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Josephine Baker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML049-SYN
- Date: 2026-07-21
- Fictional facility: St. Posthumous Health Center
- Fictional author: Colette Ashby-Nwosu, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Twelve-week review: exercise test, lipids, mood and the return to performing. **S**

## History of present illness

Ms. Baker returns about four months after the heart attack and five weeks after her sick visit for a nosebleed, which has not recurred. She completed all 36 cardiac rehabilitation sessions last week. On the treadmill test today she walked for nine minutes without chest pain or breathlessness. She has been practicing songs and dance steps at home for up to an hour, and she has an offer for a short run of concerts in the autumn. Her home blood pressure averages 122/74. She is sleeping well, her mood is better, and the rehabilitation psychologist helped her with the worry about her family and her debts. She has taken every dose of her medicines. **S**

| Element | Detail |
|---|---|
| Rehabilitation | All 36 sessions completed |
| Exercise test | Nine minutes, about 10 METs, no angina, no ischemic change |
| Home blood pressure | Average 122/74 mmHg |
| Mood | PHQ-9 3, from 7 |
| Plans | A short run of concerts in the autumn |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations or lightheadedness, including during the test |
| Respiratory | Negative | No breathlessness |
| Ears, nose, mouth, and throat | Negative | No further nosebleeds |
| Musculoskeletal | Negative | No muscle aches on atorvastatin |
| Psychiatric | Negative | Mood better; sleeping well |

5 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Clopidogrel 75 mg oral tablet: a 600 mg loading dose (eight tablets) 24 hours after the last ticagrelor, then one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Metoprolol succinate 25 mg extended-release oral tablet, one tablet daily **S**
- Lisinopril 10 mg oral tablet, one tablet daily **S**
- Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if the pain is not better 5 minutes after the first tablet **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/76 mmHg; pulse 58 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 99% on room air; weight 60.4 kg; BMI 21.4 kg/m². All vital signs are synthetic.

Total cholesterol: 128 mg/dL; LDL cholesterol: 62 mg/dL; HDL cholesterol: 54 mg/dL; Triglycerides: 72 mg/dL; ALT: 22 U/L; PHQ-9: 3; Seattle Angina Questionnaire-7 summary: 94. All results are synthetic.

## Change since baseline

- Total cholesterol: 152 mg/dL at baseline, 128 mg/dL at this visit **S**
- LDL cholesterol: 84 mg/dL (high) at baseline, 62 mg/dL at this visit **S**
- HDL cholesterol: 52 mg/dL at baseline, 54 mg/dL at this visit **S**
- Triglycerides: 80 mg/dL at baseline, 72 mg/dL at this visit **S**
- ALT: 24 U/L at baseline, 22 U/L at this visit **S**
- PHQ-9: 7 at baseline, 3 at this visit **S**
- Seattle Angina Questionnaire-7 summary: 70 at baseline, 94 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well and energetic; blood pressure 122/76, pulse 58; weight 60.4 kg |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear |
| Nose | Left nasal septum healed |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Coronary artery disease after a non-ST-elevation myocardial infarction** (I25.10). No angina; exercise capacity about 10 METs with no ischemia on the test, which is enough for stage performance. LDL 62 mg/dL, a 58% fall from 146, below the 70 mg/dL goal; ezetimibe not needed. Seattle Angina Questionnaire-7 94. **S**
   - Graded return to the stage: rehearsals at the effort reached in rehabilitation first, then full performances, with rest between shows, water, and nitroglycerin in the dressing room.
   - Continue dual antiplatelet therapy to twelve months, atorvastatin 80 mg and metoprolol.
   - Exercise most days: brisk walking or dance practice, 150 minutes a week or more.
2. **High blood pressure** (I10). At goal, 122/76; metoprolol will continue beyond the first year because of high blood pressure. **S**
   - No change.
3. **Mood after the heart attack**. PHQ-9 3 from 7: minimal symptoms with rehabilitation and its psychologist; no thoughts of self-harm. **S**
   - PHQ-2 at the preventive visit; repeat PHQ-9 if it rises.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (seated, average of two readings; home readings) | Every visit | Completed today | 122/76 mmHg; home average 122/74 |
| Examination | Weight, BMI and physical activity | Every visit | Completed today | 60.4 kg; rehabilitation completed; practicing up to an hour a day |
| Medication safety | Adherence: aspirin and P2Y12 inhibitor through the dual antiplatelet window, high-intensity statin, beta-blocker, ACE inhibitor | Every visit | Completed today | No missed doses |
| Medication safety | Bleeding on dual antiplatelet therapy (symptoms, hemoglobin when indicated) | Every visit | Completed today | One anterior nosebleed five weeks ago, managed without stopping antiplatelets (hemoglobin 11.9 g/dL then); none since |
| Laboratory | Lipid panel | Four to eight weeks after a statin start or change, then every three to twelve months | Completed today | About four months on atorvastatin 80 mg: LDL 62 mg/dL (58% fall from 146), total cholesterol 128, HDL 54, triglycerides 72; ALT 22 U/L. This is the first panel since the check due four to eight weeks after the start was missed; LDL is at goal, so the delay caused no harm and no change in treatment was postponed |
| Laboratory | Metabolic panel (potassium, creatinine, eGFR) on an ACE inhibitor | One to two weeks after a start or dose change, then every six to twelve months | Up to date | Potassium 4.7, creatinine 0.88 mg/dL eight weeks ago; next at about six months |
| Survey | Depression screen (PHQ-2, then PHQ-9) | After the infarction and periodically | Completed today | PHQ-9 3, from 7; item 9 scored 0 |
| Survey | Angina status (Seattle Angina Questionnaire-7) | At intake and every few months in the first year | Completed today | 94 |
| Examination | Stress testing or repeat angiography | Not for routine surveillance; for exercise prescription or new symptoms | Completed today | Exercise test today to prescribe exercise and guide the return to performing: about 10 METs, no angina or ischemic change |
| Imaging | Echocardiogram for left ventricular function | After the infarction if not done or if function was reduced; then only with clinical change | Not indicated | No clinical change |
| Referral | Cardiac rehabilitation | Within weeks of the infarction; 36 sessions | Completed today | All 36 sessions completed |
| Self-management | Self-management: chest-pain action plan, nitroglycerin, women's warning symptoms | Every visit | Completed today | Action plan reviewed for the dressing room and travel |
| Medication safety | Medicine and visit costs | Every visit | Completed today | Medicines affordable as generics; repayment plan in place |

## Goal progress

- Twelve months of dual antiplatelet therapy from the heart attack without interruption. In progress; target 2027-03-24. **S**
- LDL cholesterol below 70 mg/dL with at least a 50% fall. Outcome by 2026-07-21: LDL 62 mg/dL, a 58% fall from 146. **S**
- Blood pressure below 130/80 mmHg. Outcome by 2026-05-26: 126/78 in the clinic; home average 124/76. **S**
- Complete cardiac rehabilitation and return to performing. Outcome by 2026-07-21: Exercise test to about 10 METs without ischemia; graded return to rehearsals agreed. **S**
- Mood: PHQ-9 below 5 by twelve weeks. Outcome by 2026-07-21: PHQ-9 7 to 3. **S**

## Guideline basis

- 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023), American Heart Association and American College of Cardiology (Circulation 2023;148(9):e9-e119)
- 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (2025), American College of Cardiology and American Heart Association (Circulation 2025;151(13):e771-e862)
- Depression and Coronary Heart Disease: Recommendations for Screening, Referral, and Treatment: A Science Advisory From the American Heart Association (2008), American Heart Association (Circulation 2008;118(17):1768-1775)
- CMID: Clinical Monitoring Intelligence Database, ischemic heart disease and acute myocardial infarction monographs (2026), Aether Forge

## Follow-up

- Preventive visit in about eight weeks. Seven-month review in about three months with a metabolic panel and a blood count. Call 911 for chest pain not relieved five minutes after one nitroglycerin. **S**
- Next scheduled visit 2026-09-15: periodic adult preventive visit. **S**
